Citations

Clear

1575 citation(s) found for "Im, Gene".

A comprehensive gene–environment interaction analysis in Ovarian Cancer using genome‐wide significant common variants
Jensen, Allan , Wiensch, Ashley , Lee, Alice W. , Ness, Roberta B., Salvatore, Maxwell , Tworoger, Shelley S. , Whittemore, Alice S. , Sieh, Weiva , Goode, Ellen L. , Goodman, Marc T. , Chenevix‐Trench, Georgia , Rossing, Mary Anne, Webb, Penelope M. , Terry, Kathryn L. , Fortner, Renée T. , Menon, Usha , Gayther, Simon A. , Wu, Anna H. , Song, Honglin , Brooks‐Wilson, Angela , Thompson, Pamela J., Chang‐Claude, Jenny , Schildkraut, Joellen M. , Le, Nhu D. , Wentzensen, Nico, Trabert, Britton , Høgdall, Estrid , Huntsman, David G. , Pike, Malcolm C. , Pearce, Celeste Leigh , Salvatore, Maxwell , Anton-Culver, Hoda , Goode, Ellen L , Fortner, Renée T , Wu, Anna H. , Cramer, Daniel W , Modugno, Francesmary , Trabert, B , Pike, Malcolm C , Pearce, Celeste Leigh , Tworoger, Shelley S , Webb, Penelope M , Jensen, Allan , Menon, Usha , Brooks-Wilson, Angela R , Sieh, Weiva , Chenevix-Trench, Georgia , Høgdall, Estrid , Goodman, Marc T , Kim, Sehee , Wang, Miao , Tyrer, Jonathan P. , Liu, Gang , Anton‐Culver, Hoda , Olson, Sara H. , Berchuck, Andrew , Doherty, Jennifer A. , Giles, Graham G. , Ziogas, Argyrios , Bandera, Elisa V. , Cook, Linda S. , Cramer, Daniel W. , Milne, Roger L. , Winham, Stacey J. , Kjær, Susanne K. , Modugno, Francesmary , Harris, Holly R. , Pharoah, Paul D.P. , Mukherjee, Bhramar

Mayo Clinic

International Journal of Cancer | November 30, 2018 | Volume: 144 | Issue: 9 | Pages: 2192-2205

10.1002/ijc.32029 | PMID 30499236 Get It

As a follow‐up to genome‐wide association analysis of common variants associated with ovarian carcinoma (cancer), our study considers seven well‐known ovarian cancer risk factors and their interactions with 28 genome‐wide significant common genetic variants. The interaction analyses were based on data from 9971 ovarian cancer cases and 15,566 controls from 17 case–control studies. Likelihood ratio and Wald tests for multiplicative interaction and for relative excess risk due to additive interaction were used. The top multiplicative interaction was noted between oral contraceptive pill (OCP) use (ever vs. never) and rs13255292 (p value = 3.48 × 10−4). Among women with the TT genotype for this variant, the odds ratio for OCP use was 0.53 (95% CI = 0.46–0.60) compared to 0.71 (95%CI = 0.66–0.77) for women with the CC genotype. When stratified by duration of OCP use, women with 1–5 years of OCP use exhibited differential protective benefit across genotypes. However, no interaction on either the multiplicative or additive scale was found to be statistically significant after multiple testing correction. The results suggest that OCP use may offer increased benefit for women who are carriers of the T allele in rs13255292. On the other hand, for women carrying the C allele in this variant, longer (5+ years) use of OCP may reduce the impact of carrying the risk allele of this SNP. Replication of this finding is needed. The study presents a comprehensive analytic framework for conducting gene–environment analysis in ovarian cancer.
Autologous Gene and Cell Therapy Provides Safe and Long-Term Curative Therapy in A Large Pig Model of Hereditary Tyrosinemia Type 1
Nicolas, Clara T., Allen, Kari L. , Mao, Shennen A. , Elgilani, Faysal, Glorioso, Jaime , Amiot, Bruce , VanLith, Caitlin J. , Guthman, Rebekah M., Du, Zeji , Chen, Harvey , Kaiser, Robert A. , Nyberg, Scott L. , Lillegard, Joseph B. , Hickey, Raymond D, Allen, Kari, Mao, Shennen, VanLith, Caitlin, Guthman, Rebekah, Mao, Shennen A , Hickey, Raymond , Harding, Cary O.

Mayo Clinic

Cell Transplantation | November 27, 2018 | Volume: 28 | Issue: 1 | Pages: 79-88

10.1177/0963689718814188 | PMID 30477316 Get It

Orthotopic liver transplantation remains the only curative therapy for inborn errors of metabolism. Given the tremendous success for primary immunodeficiencies using ex-vivo gene therapy with lentiviral vectors, there is great interest in developing similar curative therapies for metabolic liver diseases. We have previously generated a pig model of hereditary tyrosinemia type 1 (HT1), an autosomal recessive disorder caused by deficiency of fumarylacetoacetate hydrolase (FAH). Using this model, we have demonstrated curative ex-vivo gene and cell therapy using a lentiviral vector to express FAH in autologous hepatocytes. To further evaluate the long-term clinical outcomes of this therapeutic approach, we continued to monitor one of these pigs over the course of three years. The animal continued to thrive off the protective drug NTBC, gaining weight appropriately, and maintaining sexual fecundity for the course of his life. The animal was euthanized 31 months after transplantation to perform a thorough biochemical and histological analysis. Biochemically, liver enzymes and alpha-fetoprotein levels remained normal and abhorrent metabolites specific to HT1 remained corrected. Liver histology showed no evidence of tumorigenicity and Masson’s trichrome staining revealed minimal fibrosis and no evidence of cirrhosis. FAH-immunohistochemistry revealed complete repopulation of the liver by transplanted FAH-positive cells. A complete histopathological report on other organs, including kidney, revealed no abnormalities. This study is the first to demonstrate long-term safety and efficacy of hepatocyte-directed gene therapy in a large animal model. We conclude that hepatocyte-directed ex-vivo gene therapy is a rational choice for further exploration as an alternative therapeutic approach to whole organ transplantation for metabolic liver disease, including HT1.
Is Enhancement the Price of Prevention in Human Gene Editing?
Conley, John M., MacKay, Douglas , Kuczynski, Kristine J. , Cadigan, R. Jean , Meagher, Karen M. , Juengst, Eric T. , Henderson, Gail E. , Walker, Rebecca L. , Saylor, Katherine Witte , Waltz, Margaret

Mayo Clinic

The CRISPR Journal | November 26, 2018 | Volume: 1 | Issue: 6 | Pages: 351-354

10.1089/crispr.2018.0040 | PMID 31021238 Get It

Abstract New gene-editing tools challenge conventional policy proscriptions of research aimed at either human germline gene editing or human enhancement by potentially lowering technical barriers to both kinds of intervention. Some recent gene-editing reports have begun to take up the prospect of germline editing, but most experts are in broad agreement that research should prioritize medical applications over attempts to enhance human traits. However, there is little consensus about what counts as human enhancement in this context, or how to deal with the issues it flags. Moreover, several influential reports interpret medical applications to include disease prevention as well as treatment as a goal for gene-editing research. This challenges the current policy consensus because using gene editing to prevent disease would incidentally facilitate human enhancement applications in a variety of ways. If such research efforts are penalized by policy concerns about enhancement, then their preventive health benefits could be lost. To avoid being caught off guard by such challenges, science policy makers will need to think more carefully about what “prevention” might mean in the gene-editing context, and develop research governance that can anticipate and address the human enhancement concerns it will raise. To accomplish the latter, the scope of policy making will need to expand from its narrow focus on human clinical trials to engage with basic researchers driving the translational pipeline toward preventive gene editing and the science policy makers who have to address its “off-label” uses.
2029. Comparison of Primers Amplifying Two Different Regions of the 16S Ribosomal RNA Gene for Microbiologic Diagnosis of Cardiovascular Implantable Electronic Device Infection
Garrigos, Zerelda Esquer , Greenwood‐Quaintance, Kerryl E. , Vijayvargiya, Prakhar , Thoendel, Matthew , Friedman, Paul A. , Sohail, M. Rizwan , Patel, Robin

Mayo Clinic

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S591-S591

10.1093/ofid/ofy210.1685 Get It

A tropomyosin-receptor kinase-fused gene mutation associates with vacuolar myopathy
Madigan, Nicolas N. , Tracy, Jennifer A., Litchy, William J. , Niu, Zhiyv , Chen, Chunhua , Ling, Kun , Milone, Margherita , Niu, Zhiyv

Mayo Clinic

Neurology Genetics | November 7, 2018 | Volume: 4 | Issue: 6 | Pages: No page available

10.1212/nxg.0000000000000287 | PMID 30643850 Get It

PATH-26. NEURO-ONCOLOGY NEXT-GENERATION SEQUENCING 219-GENE PANEL FOR COMPREHENSIVE CLINICAL TESTING
Fritcher, Emily Barr, Zysk, Christopher, Voss, Jesse S. , Wu, Xianglin, Klee, Eric W. , Kipp, Benjamin R. , Jenkins, Robert B. , Ida, Cristiane M. , Fritcher, Emily G. Barr , Balan, Jagadheshwar , Kollmeyer, Thomas M. , Raghunathan, Aditya , Giannini, Caterina

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi164-vi164

10.1093/neuonc/noy148.682 Get It

GENE-11. SMALL TERMINAL ALTERATIONS AND ALTERNATIVE LENGTHENING OF TELOMERES ARE A FEATURE OF IDH-MUTANT, 1p/19q NON-CODELETED GLIOMAS
Yamada, Seiji , Jacobs, Joshua , Decker, Paul A. , Kosel, Matt, Caron, Alissa, Halder, Chandralekha, Ruiz, Vanessa , Kipp, Benjamin R. , Voss, Jesse S. , Vaubel, Rachel, Jenkins, Robert B. , Brown, Desmond , Praska, Corinne , Kollmeyer, Thomas M. , Decker, Paul A. , Kosel, Matthew , Giannini, Caterina

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi105-vi105

10.1093/neuonc/noy148.438 Get It

GENE-29. DLL3 AND ETV1 ARE INACTIVATED/METHYLATED IN CIC WILD-TYPE, IDH-MUTATED, 1p/19q-CODELETED GLIOMA
Kosel, Matthew , Decker, Paul A. , Caron, Alissa, Sarkar, Gobinda , Halder, Chandralekha, Tian, Shulan , Eckel‐Passow, Jeanette E. , Jenkins, Robert B. , Lachance, Daniel Honore , Decker, Paul A. , Kollmeyer, Thomas M. , Drucker, Kristen , Knight, Andrew, Abyzov, Alexej , Burns, Terry C. , Giannini, Caterina

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi109-vi109

10.1093/neuonc/noy148.455 Get It

GENE-20. A NOVEL K-M ENHANCER REGULATES TEMOZOLOMIDE RESISTANCE AND TUMOR GROWTH IN GLIOBLASTOMA
Chen, Xiaoyue , Gan, Haiyun , Fang, Dong, Kitange, Gaspar J. , Hu, Zeng, Chen, Xiaoyue, Zhang, Minjie , Lee, Jeong‐Heon , Fang, Dong, He, Lihong , Zhang, Zhiguo , Sarkaria, Jann N.

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi107-vi107

10.1093/neuonc/noy148.446 Get It